Efficacy and safety of high-voltage versus standard-voltage pulsed radiofrequency ablation for patients with neuropathic pain: protocol for a systematic review and meta-analysis

Yitong Jia, Zheng Wang, Yanhui Ma, Tengteng Wang, Kunpeng Feng, Tianlong Wang

INTRODUCTION

Neuropathic pain (NP) is a common chronic pain condition caused by lesions or diseases affecting the somatosensory nervous system, including trigeminal neuralgia (TN), peripheral nerve injury pain, painful polyneuropathy, postherpetic neuralgia and central poststroke pain. Epidemiological data have reported that the global prevalence of NP is approximately 6.9%–10%. NP is a refractory pain syndrome with a long duration of occurrence, frequent recurrent attacks and poor response to traditional analgesics. Most patients with NP suffer from ongoing or intermittent spontaneous pain accompanied by burning, pricking and squeezing sensations, and have a poor quality of life (QoL). Therefore, finding an effective treatment option for NP and improving patients’ QoL is of great importance.

In recent years, pulsed radiofrequency (PRF) ablation, a new type of neuromodulation technique, has been successfully applied in the treatment of NP. Different from continuous radiofrequency, which produces heat by friction and vibration, leading to thermocoagulation, denaturation and necrosis of the target tissue, PRF provides pulsed energy waves followed by a 480 ms heat dissipation interval, and the temperature does not exceed 42°C. PRF treatment exerts its effect via the modulation of nerve function, which is a result of the electric field effect and not the impedance of pain signal transduction, thus, PRF ablation is a
non-destructive technique that can be repeatedly applied without causing nerve tissue damage.

The standard proposed PRF parameters are set as follows: an output voltage of 45 V, temperature of 42°C, pulse frequency of 2 Hz, output frequency of 500 kHz, continuous current action of 20 ms and intermission period of 480 ms. Recently, scholars have attempted to treat patients with NP using high-voltage PRF ablation. Teixeira and Sluijter first reported that a high-voltage PRF ablation of 60 V used to treat patients with discogenic pain attained satisfactory efficacy that lasted over 3 months. In 2013, Luo et al found that the postoperative numeric rating scale (NRS) score had a significant negative correlation with the output voltage of PRF. Afterwards, Luo et al compared the efficacy of high-voltage PRF with standard-voltage PRF for idiopathic TN patients who responded poorly to oral carbamazepine or nerve blockade by steroid, and the results revealed the 1 year effective rate of high-voltage PRF (69%) was significantly higher than that in the standard-voltage PRF treatment (19%) (p=0.000). Additionally, they compared the efficacy of high-voltage PRF and standard voltage PRF for refractory neuralgia infraorbital nerve therapy, and reported that high-voltage PRF ablation could achieve higher response rates at 1 month, 3 months, 6 months and 1 year post procedure. Jia et al retrospectively analysed the medical data of patients with idiopathic TN undergoing PRF. The study found that for patients who did not respond to the first PRF treatment and underwent the second PRF treatment, a higher dose of output voltage than the initial one could achieve improved analgesic effect.

However, the number of patients who experienced mild numbness postoperatively was greater in the high-voltage group (27%) than in the standard-voltage group (13%). In addition, a randomised controlled trial (RCT) conducted by Wan et al showed that the scores were significantly lower in the high-voltage group than in the standard-voltage group at 3 and 6 months; however, no significant difference was observed at 1 month after treatment. A study by Wan et al revealed that the incidence of ecchymoses in the high-voltage group (19.2%) was higher than that in the standard-voltage group (12.1%). As a result, further analysis is required to determine whether the efficacy of high-voltage PRF ablation at different timepoints is superior to that of standard-voltage PRF ablation, and whether high-voltage PRF ablation is a safe treatment method for NP.

The primary objectives of this study will be to compare the efficacy and safety of high-voltage PRF ablation and standard-voltage PRF ablation for the treatment of NP at different timepoints postoperatively through a systematic review and meta-analysis of RCTs.

METHODS

This protocol was developed according to the reporting guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols statement. Our systematic review will be conducted in accordance with the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions. Any amendments made to this protocol and the whole review process will be updated in a timely manner on the PROSPERO registration and the final manuscript.

Criteria for considering eligible studies

Types of studies

Only RCTs will be included. All studies must be published in English. Experimental animal studies will be excluded.

Participants

Patients with NP conditions recognised and defined by the International Association for the Study of Pain will be included. NP is initiated or caused by a primary lesion or dysfunction of the nervous system. Studies regarding diabetic neuropathy, complex regional pain syndrome type 1, low back pain without radicular pain and postsurgical pain will be excluded.

Interventions and comparators

We will examine trials investigating high-voltage PRF treatment for patients with NP. The high-voltage PRF treatment will be set to the manual pulse mode: the initial voltage will be 40 or 45 V, and the output voltage will then be gradually increased to the highest voltage the patient can tolerate (temperature control below 50°C). The comparator will be the standard PRF treatment.

Outcome measures

The primary outcome of this meta-analysis is the efficiency rate in patients with NP. The predefined timepoints for the efficiency rate will be 1 month, 3 months and 6 months after the procedure. Additionally, 1-year or 2-year timepoint will also be considered. Treatment efficiency recurrence is defined as a pain reduction of greater than 50% after treatment compared with pre-surgery. Secondary outcomes will include (NRS) or visual analogue scale (VAS) score, time to take effect, rescue drug dosage, QoL determined using a health questionnaire (SF-36) at 1 month, 3 months and 6 months postoperatively, and incidence of adverse events (AEs).

Information sources and search strategy

A computer-based search strategy will be designed by an experienced librarian and revised by another expert librarian according to the Peer Review of Electronic Search Strategies checklist. The primary source of the literature will be the following major electronic databases: PubMed/MEDLINE, EMBASE, Web of Science and the Cochrane Library (from the date of inception until 15 March 2022). The secondary source of potentially relevant research includes conference proceedings for relevant abstracts, clinical trials registers (ClinicalTrials.gov) and the WHO’s International Clinical Trial Registry Platform to identify ongoing studies. The search will encompass a broad range of terms and keywords.
related to ‘high-voltage’, ‘pulsed radiofrequency’, ‘neuropathic pain’ and ‘RCT’. The detailed search strategy is presented in online supplemental file 2.

**Data selection and analysis**

**Study selection**

We will use the Population, Intervention, Comparison, Outcome model\(^30\) to determine the specific criteria for selecting studies. Two reviewers (YJ and GF) will independently screen and select the relevant studies. During the initial screening, reviewers will determine whether the study could be included by screening the titles and abstracts retrieved via database search. We will screen the full texts retained from the initial selection of articles to include studies that meet the eligibility criteria. Disagreements between the two reviewers will be resolved by a third reviewer (TeW). If several studies present data from the same study population or multiple publications from the same study are published in chronological order, the study with the most direct interventions or the largest sample size will be selected. The same methods will be used for citation, reference screening and selection, as well as for protocols registered in clinical trial registries.

**Data extraction**

A standardised electronic form for data extraction will be created by ZW. Two reviewers (YJ and GF) will independently extract the following data: study characteristics (eg, name of the first author, year of publication, type of study, sample size), population characteristics (eg, age, gender, disease duration, medical history, preoperative pain intensity and follow-up period) and outcome data (eg, primary and secondary outcomes and any AEs caused by PRF treatment). Similarly, a third reviewer will be required to resolve any discrepancies. We will attempt to contact the study authors by email or post for further information in case of any ambiguity or insufficient information. Table 1 presents the characteristics of the studies that will be included.

**Assessment of risk-of-bias and quality-of-evidence assessment**

Two reviewers (YJ and GF) will independently assess the risk of bias (RoB) and a third reviewer (ZW) will resolve discrepancies. The RoB of RCTs will be assessed according to items in the Cochrane Collaboration’s tool.\(^26\)

We will evaluate the overall quality of the body of evidence in accordance with the Grading of Recommendations Assessment, Development and Evaluation methodology,\(^31\) which examines study design, RoB, inconsistency, indirectness and imprecision. Accordingly, quality of evidence will be rated as high, moderate, low or very low.

**Data synthesis and analysis**

Meta-analyses will be conducted using the standard meta-analysis software (RevMan V.5.3, The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen, Denmark). We will compute standardised mean differences and 95% CIs for continuous outcomes and risk ratios with 95% CI for binary outcomes. A two-tailed p value<0.05 will be considered statistically significant. We will assess the intervention effects between high-voltage PRF and standard-voltage PRF using preintervention to postintervention changes. When the data in the literature are expressed as median values and quartiles, we will use mathematical operations to transform them into mean and SD.\(^22\)\(^33\) Additionally, we will use forest plots to visualise pooled estimates and the extent of heterogeneity among studies. Heterogeneity will be assessed using the I\(^2\) statistic. I\(^2\)>50% is an indication of substantial heterogeneity, and in such cases the random effects model will be used to analyse the outcomes; otherwise, a fixed-effect model will be applied. If heterogeneity is observed, we will perform subgroup analysis according to prespecified variables, such as study design, intervention characteristics or RoB. The sources of heterogeneity will be explored using sensitivity analysis. A funnel plot\(^34\) or Egger test\(^35\) will be used to assess publication bias.

**Patient and public involvement**

Since our study is a systematic review based on published literature, no patients will be involved.

**DISCUSSION**

Our study aims to compare the efficacy and safety of high-voltage PRF ablation and standard-voltage PRF ablation

| Table 1 | Main characteristics of RCTs comparing the efficacy and safety of high-voltage PRF and standard-voltage PRF for the treatment of NP |
|---------|----------------------------------------------------------------------------------------------------------------------------------|
| Study ID | Sample size | Types of neuropathic pain | Setting | Duration | Number of female (%) | Male (%) | patients | Age (years) | Preoperative pain (VAS/ NRS) | Preoperative QoL | Postoperative pain (VAS/ NRS) | Postoperative QoL | Complications |
|---------|--------------|---------------------------|---------|----------|----------------------|---------|----------|-------------|-----------------------------|----------------|-----------------------------|----------------|--------------|
| A       |              |                           |         |          |                      |         |          |             |                             |                 |                             |                 |              |
| B       |              |                           |         |          |                      |         |          |             |                             |                 |                             |                 |              |
| C       |              |                           |         |          |                      |         |          |             |                             |                 |                             |                 |              |
| ......  |              |                           |         |          |                      |         |          |             |                             |                 |                             |                 |              |

NP, neuropathic pain; NRS, numeric rating scale; PRF, pulsed radiofrequency; QoL, quality of life; RCT, randomized controlled trials; VAS, visual analog scale.
for NP therapy and provide clinical evidence for the selection of PRF modes in clinical practice via synthesising RCTs in journal publications. This study has some limitations. The sample size of the eligible RCTs might not be large and the accuracy of our research conclusions might be biased due to language limitations, as we will only include studies published in English. Overall, the study findings will provide comprehensive information for future study designs in terms of interventional treatment of NP.

Author affiliations
1 Department of Anesthesiology, Xuanwu Hospital Capital Medical University, Beijing, China
2 Department of General Surgery, Xuanwu Hospital Capital Medical University, Beijing, China
3 Department of Thoracic Surgery, Xuanwu Hospital Capital Medical University, Beijing, China
4 Xuanwu Hospital, Capital Medical University, Beijing, China

Acknowledgements
The authors would like to thank the participants of the study for their cooperation.

Contributors
YJ, TW, TeW and TiW made substantial contributions to clinical study design, YJ, YM and GF made substantial contributions to manuscript preparation, editing and review. MF made contributions to English language editing. YM, KF and GF consulted about clinical issues. YJ, YM, TeW and TiW have given final approval of the version to be published. YJ, ZW and YM contributed equally to this work. TiW is responsible as corresponding author.

Funding
This study was funded and sponsored by Beijing Municipal Medical Science Institute-Public Welfare Development Reform Pilot Project (Capital Medical Research No. 2019-2).

Competing interests
None declared.

Patient and public involvement
Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication
Not applicable.

Provenance and peer review
Not commissioned; externally peer reviewed.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Yitong Jia http://orcid.org/0000-0002-3872-9038
Zheng Wang http://orcid.org/0000-0001-6262-2102

REFERENCES
1 Baron R, Binder A, Waaler G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010;9:807–19.
2 van Hecke O, Austin SK, Khan RA, et al. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain 2014;155:654–62.
3 Colloca L, Ludman T, Bouhassira D, et al. Neuropathic pain. Nat Rev Dis Primers 2017;3:17002.
4 Park CH, Lee SH, Lee PB. Intradiscal pulsed radiofrequency application duration effect on lumbar discogenic low back pain. Pain Physician 2020;23:E535–40.
5 Martin DC, Willis ML, Mullinax LA, et al. Pulsed radiofrequency application in the treatment of chronic pain. Pain Pract 2007;7:31–5.
6 Kim K, Jo D, Kim E. Pulsed radiofrequency to the dorsal root ganglion in acute herpes zoster and postherpetic neuralgia. Pain Physician 2017;20:E411–8.
7 Shi Y, Wu W. Treatment of neuropathic pain using pulsed radiofrequency: a meta-analysis. Pain Physician 2016;19:429–44.
8 Jia Y, Shrestha N, Wang X, et al. The long-term outcome of CT-guided pulsed radiofrequency in the treatment of idiopathic glossopharyngeal neuralgia: a retrospective multi-center case series. J Pain Res 2020;13:2093–102.
9 Vuka I, Marcíuñ T, Došenovic S, et al. Efficacy and safety of pulsed radiofrequency as a method of dorsal root ganglia stimulation in patients with neuropathic pain: a systematic review. Pain Med 2020:21:3320–43.
10 Ren H, Zhao C, Wang X, et al. The efficacy and safety of the application of pulsed radiofrequency, combined with low-temperature continuous radiofrequency, to the gasserian ganglion for the treatment of primary trigeminal neuralgia: study protocol for a prospective, open-label, Parall. Pain Physician 2021;24:89–97.
11 Contreras Lopez WO, Navarro PA, Vargas MD, et al. Pulsed radiofrequency versus continuous radiofrequency for facet joint low back pain: a systematic review. World Neurosurg 2019;122:390–6.
12 Wu C-Y, Lin H-C, Chen S-F, et al. Efficacy of pulsed radiofrequency in herpetic neuralgia: a meta-analysis of randomized controlled trials. Clin J Pain 2020;36:887–95.
13 Wu H, Zhou J, Chen J, et al. Therapeutic efficacy and safety of radiofrequency ablation for the treatment of trigeminal neuralgia: a systematic review and meta-analysis. J Pain Res 2019;12:423–41.
14 Li H, Ding Y, Zhu Y, et al. Effective treatment of postherpetic neuralgia at the first branch of the trigeminal nerve by high-voltage pulsed radiofrequency. Front Neurol 2021;12:746035.
15 Sam J, Catapano M, Sahni S, et al. Pulsed Radiofrequency in Interventional Pain Management: Cellular and Molecular Mechanisms of Action - An Update and Review. Pain Physician 2021;24:525–32.
16 Vanneste T, Van Lantschoot A, Van Boxem K, et al. Pulsed radiofrequency in chronic pain. Curr Opin Anesthesiol 2017;30:577–82.
17 Teixeira A, Sluijtter ME. Intradiscal high-voltage, long-duration pulsed radiofrequency for discogenic pain: a preliminary report. Pain Med 2006;7:324–8.
18 Luo F, Meng L, Wang T, et al. Pulsed radiofrequency treatment for idiopathic trigeminal neuralgia: a retrospective analysis of the causes for ineffective pain relief. Eur J Pain 2013;17:1189–92.
19 Fang L, Tao W, Jingjing L, et al. Comparison of High-voltage- with Standard-voltage pulsed radiofrequency of gasserian ganglion in the treatment of idiopathic trigeminal neuralgia. Pain Pract 2015;15:595–603.
20 Luo F, Wang T, Shen Y, et al. High voltage pulsed radiofrequency for the treatment of refractory neuralgia of the infraorbital nerve: a prospective double-blinded randomized controlled study. Pain Physician 2017;20:271–9.
21 Fang L, Jia Z. In Response to Comments on “Long-term Follow-up of Pulsed Radiofrequency Treatment for Trigeminal Neuralgia: Kaplan-Meier Analysis in a Consecutive Series of 149 Patients”. Pain Physician 2022;25:E609.
22 Silva V. Comments on “Long-term Follow-up of Pulsed Radiofrequency Treatment for Trigeminal Neuralgia: Kaplan-Meier Analysis in a Consecutive Series of 149 Patients”. Pain Physician 2022;25:E608.
23 Zipu J, Hao R, Chunmei Z, et al. Long-Term follow-up of pulsed radiofrequency treatment for trigeminal neuralgia: Kaplan-Meier analysis in a consecutive series of 149 patients. Pain Physician 2021;24:E1263–71.
24 Wan C-F, Song T. Comparison of two different pulsed radiofrequency modes for prevention of postherpetic neuralgia in elderly patients with Acute/Subacute trigeminal herpetic zoster. Neuromodulation 2021; doi:10.1111/ner.13457. [Epub ahead of print: 18 May 2021] (published Online First: 2021/05/20).
25 Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2016;354:i4086.
26 Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for systematic reviews of interventions. *Cochrane Database Syst Rev* 2019;10:Ed000142.

27 Ochoa JL. Neuropathic pain: redefinition and a grading system for clinical and research purposes. *Neurology* 2009;72:1282–3.

28 Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. *BMJ* 1992;305:160–4.

29 McGowan J, Sampson M, Salzwedel DM, et al, PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. *J Clin Epidemiol* 2016;75:40–6.

30 Huang X, Lin J, Demner-Fushman D. Evaluation of PICO as a knowledge representation for clinical questions. *AMIA Annu Symp Proc* 2006;2006:358–63.

31 Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol* 2011;64:383–94.

32 Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol* 2014;14:135.

33 Shi J, Luo D, Wan X. Detecting the skewness of data from the sample size and the five-number summary 2020.

34 Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629–34.

35 Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ* 2011;343:d4002.